From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide hydrate
Clinical data
Trade names Stivarga
  • AU: D
  • US: D (Evidence of risk)
Legal status
Routes of
Pharmacokinetic data
Bioavailability 69-83%
Protein binding 99.5%
Metabolism Hepatic (UGT1A9-mediated)
Biological half-life 20-30 hours
Excretion Faeces (71%), urine (19%)
CAS Number 755037-03-7
ATC code L01XE21
PubChem CID: 11167602
ChemSpider 28295228
KEGG D10138
ChEBI CHEBI:68647 YesY
Synonyms BAY 73-4506
Chemical data
Formula C21H17ClF4N4O4
Molecular mass 482.82 g mol

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types.[1] By 2015 it had 2 US approvals for advanced cancers.

Approvals and indications[edit]

Metastatic colorectal cancer[edit]

Regorafenib demonstrated to increase the overall survival of patients with metastatic colorectal cancer[2] and has been approved by the US FDA on September 27, 2012.[3]

After a manufacturer's appeal Regorafenib was restored to the list of treatments funded by the English Cancer Drugs Fund.[4]

Advanced gastrointestinal stromal tumours[edit]

On February 25, 2013 the US FDA expanded the approved use to treat patients with advanced gastrointestinal stromal tumors that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease. In a clinical study with 199 patients regorafenib treated patients had a delay in tumor growth (progression-free survival) that was, on average, 3.9 months longer than patients who were given placebo.[5]

Clinical trials[edit]

MetastaticCRC: After the CORRECT trial, two phase 3 trials (CONSIGN, CONCUR) showed benefits compared to placebo. Regorafenib dosing was 150 or 160 mg/d for first 3 weeks of each 4 week cycle.[6]

Adverse effects[edit]

Regorafenib is being approved with a Boxed Warning alerting patients and health care professionals that severe and fatal liver toxicity occurred in patients treated with regorafenib during clinical studies. Serious side effects, which occurred in less than one percent of patients, were liver damage, severe bleeding, blistering and peeling of skin, very high blood pressures requiring emergency treatment, heart attacks and perforations (holes) in the intestines. The most common side effects reported in patients treated with regorafenib include weakness or fatigue, loss of appetite, hand-foot syndrome (also called palmar-plantar erythrodysesthesia), diarrhoea, mouth sores (mucousitis), weight loss, infection, high blood pressure, and changes in voice volume or quality (dysphonia).[7]